Ann: Interim data from MSKCC study, page-38

There are aspects of this company, its drug, its share price....that I do believe are seen once in a lifetime (of investing).

Melodramatic ? and maybe words of others even used from time to time, with their stock investment - but oh no, this is different.

The previous post - beyond any doubt whatsoever highlights what the potential of PI3K and radiation. Only paxalisib - only paxalisib is in clinical studies in this combination. You know the published results so far - millions of cancer patients are prescribed radiation every day.

-----------------------------------------
So what do you think - is the situation here unprecedented FOR A US$10 MILLION COMPANY ? or what.


Also I can't be bothered to further explain - but there is a 50% chance in 9 months -the company will seek approval to market this drug paxalisib for GBM (first new drug for GBM in 15 years). At a likely gross annual sale of US$600m- profit US$300m means the drug would be worth US$3 BILLION for GBM.
-----------------------------------------------------------------------------------------------

Still investing at 90 years of age - I don't think you will see this situation again.